Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: Biotech start-ups elevate Hong Kong’s regional role

Albert Wong argues that biomedical technology should not be ignored and explains how the Hong Kong Science and Technology Parks Corporation can support it.

Amid all the attention given to robotics, artificial intelligence, big data and IoT, one of the most attractive areas of technological advance is often overlooked: biomedical technology.

For some, the costs and risks associated with the industry make it less attractive as an investment proposition. But in Hong Kong Science Park, we view it differently. A mix of groundbreaking technologies and a strategic focus to convert Hong Kong into a regional biomedical hub make this sector highly attractive.

Add to that the growing health awareness in the region, where lifestyles, changing diets and growing wealth, together with ageing populations, are creating health issues once associated more with the western world. Rising demand and pressure on healthcare services are pushing up medical costs, but at the same time, creating huge potential for the growth of biomedical sector.

Hong Kong is well-placed to support biomedical technology development. It has the world’s biggest market – China – on its doorstep, a large talent pool, access to funding, with a legal structure and a finance system that gives confidence to both inventors and investors. At Hong Kong Science Park, besides its facilities and a lot of like-minded people, close working relationships with the city’s eight world-class universities mean there is a lot of talent available. Hong Kong Science and Technology Parks Corporation (HKSTP) facilitates knowledge transfer and nurtures talents through connections with stakeholders to provide technical and financial support for the technological innovation and commercialisation.

For the field of biomedical technology, HKSTP fosters innovation and development of products such as futuristic diagnostic devices or life-saving treatments to address the society’s health needs. On the technical aspect, HKSTP provides laboratories and service support at Science Park, such as the Biomedical Technology Support Centre. These can be used on a time-share basis, while staffed by professional scientists, all of which would be beneficial to start-ups often operating on a shoestring budget. The Park is also an ideal platform for sharing expertise and business collaborations, as well as investment-matching, for the entrepreneurs to follow their r&d dreams.

As a result, the Park now hosts over 100 biomedical companies and start-ups with business scope spreading across medical devices, stem cells, genomics and regenerative medicine, molecular diagnosis, as well as research and development on Chinese and Western medicines. All these different subspecialties contribute to an ecosystem that’s highly conducive to biomedical research.

For drug r&d, there are strong synergies for Hong Kong and mainland China, particularly in areas where researchers have common objectives, such as the development of early disease diagnosis and precision medicine for treating cancers. Because of its bilingual system and largely Chinese population, Hong Kong is an ideal place to draw on international research and expertise, and adapt it to best suit local needs.

More importantly, clinical data from Hong Kong is recognised by the China Food and Drug Administration for registration and approval purposes, making it an ideal testing ground for emerging therapies and devices which are tailor-made to the population’s genetic make-up to achieve optimal efficacy.

In Asia, healthcare is heavily burdened by rapidly ageing populations and increasing chronic diseases prevalence, especially cancer. At present, lung cancer is the leading cause of cancer deaths worldwide. Every year, it causes more than 1.6 million deaths – more than breast, colon and prostate cancer combined. And among all the cases, 51% of the world’s lung cancer cases occur in Asia, while 21% of cancer deaths in Asia are due to lung cancer. In China, the world’s largest consumer of tobacco, about two-thirds of young Chinese men smoke, and it is estimated that about half of them will die as a result of it if they don’t stop.

The good news is that local innovation is driving advances in cancer treatment. One company at the forefront is Hong Kong-based Sanomics, which specialises in genomics technology and has dramatically altered the delivery of treatments to individual lung cancer patients based on the ground-breaking new concept of precision medicine.

With precision medicine, Sanomics is shifting from body testing to DNA analysis to identify more targeted therapies for cancer. Precision medicine is a sequencing approach that looks for and examines abnormal changes in genes. It supports the decision-making of oncologists based on information about genetic alterations in tumour DNA. Specific treatments can then be aimed at abnormalities or mutations which cause the growth of cancer cells.

What is unique about Sanomics’ approach is that it uses bodily fluids, such as blood, to screen for genetic alterations when tumour tissues are not available or when it’s not possible to do a biopsy on a patient for conventional diagnostic purposes. It adopts a new process known as liquid biopsy. It is faster, more convenient and more practical in the clinical setting associated with less invasive procedures for the subjects.

Sanomics is an excellent example of the successful commercialisation of academic research in Hong Kong – developing from a proof of scientific concept in university to providing commercial products and services. The company started from HKSTP’s incubation programme, in which the Park would provide support on financial aid, laboratory and technical needs, as well as collaboration matching with corporations who are looking for partners. Sanomics soon established a collaboration with a leading global pharmaceutical company to test and find the optimal treatment for lung cancer patients based on their genetic make-up.

On the back of its success to date, Sanomics is now building Asia’s first hub for liquid biopsy in Hong Kong, and will lead the region in the use of genomics for personalised management of cancer.

Research and development, such as that which supported the growth in liquid biopsy diagnostics is driven by the private sector, especially in late-stage research. In Hong Kong, there is no shortage of funding, but investors tend to need more education on longer term, early-stage investment. So we play to the different investor strengths and needs, tapping universities particularly for early-stage research.

Hong Kong is fortunate in having some of the world’s finest universities, all with different specialisations from lab-based research and product development to in-the-field community healthcare. These are particularly good at early-stage research, but less so when r&d reaches the commercialisation stage. In these situations, a research licensing model has proved effective. The late-stage research and commercialisation then go to private sector companies, such as Sanomics at Hong Kong Science Park, which have the expertise to progress its development.

The Science Park has different means to support start-ups, including its Corporate Venture Fund and other funding schemes. It also holds investment-matching events such as the Elevator pitch, to be held in November, in conjunction with Jumpstarter. Through arranging such regular matching events, HKSTP helps to pair angel investors and venture capitalists with Park companies to accelerate their biomedical innovations and developments.

An investment ecosystem is a critical component to technology development. The biomedical sector, like other technology sectors, needs smart investors to bring up the good ones, and prune the not-so-good ones. Biomedical technologies take a long time to develop and to mature. Development and regulatory processes cost money and time. Investors have to be ready to partner, bringing expertise and patience. The investment cycles often include long drawn-out periods of non-profit or even non-revenue. The entry barrier is high and the risk is high. Smart and strategic investors are critical to the growth of biomedical. We are lucky that we have some of these in Hong Kong.

Albert Wong is CEO of the Hong Kong Science and Technology Parks Corp.

Posted on: 12/09/2017 UTC+08:00


News

SGX-listed Acromec, which designs and builds medical and sterile cleanrooms, has secured another contract in the healthcare sector valued at S$2.9 million (US$2.1 million). It is expected to be completed by the end of the year.
Sydney-based 1st Group, the Australian digital health, media and technology group, has appointed Richard Rogers as chief financial officer. He joins from Lenovo Australia & New Zealand.
Asia-focused market expansion services provider DKSH is to sell its healthcare business in China to Warburg Pincus for SFr100 million (US$100.7 million).
Summerset Group, New Zealand’s third-largest listed retirement village operator, has said that it expects underlying half year profits to jump between 21% and 26% to NZ$43 million (US$29.4 million) and NZ$45 million.
Patient flow management firm Jayex Healthcare has signed a binding licence agreement with medical cannabis company MediCann NZ under which it will be granted the exclusive use and application of its technologies in New Zealand in connection with their proposed sale and distribution of medical cannabis products in line with the expected deregulation in New Zealand of medical cannabis.
IDS Medical Systems Group, a leading medical supply-chain solutions company in Asia, and Tencent-backed We Doctor have formed idsMED WeDoctor China, the country’s first smart medical supply chain solutions and procurement company.
Australian medtech company Resonance Health has signed an alliance partner agreement with Blackford Analysis which grants it rights to integrate and combine Resonance Health products with, or sell and license Resonance Health products in connection with the host application.
Malaysian medical services company Adventa has scrapped plans to raise M$80.2 million (US$20.3 million) after Top Glove Corporation, the world’s largest rubber glove manufacturer, announced legal proceedings against its parent Adventa Capital and two of its directors.



Analysis

Ping An Healthcare and Technology, formerly known as Good Doctor, has signed contracts with nearly 200 large corporations, including Vanke, Greentown, Bank of China, China Telecom, China National Nuclear Power, Evergrande Group and provides services to nearly 1.5 million employees, covering 27 provinces, autonomous regions and municipalities.
Earlier this week, Cigna Corporation released the results of its 2018 Cigna 360° Well-Being Survey – Future Assured. The findings, which were tracked over a four year period, show rising awareness of the need to prepare for old age, which includes being continually active and financially independent. As a result, people are working harder today, and increasingly calling on employers to help in managing workplace stress.
Auckland-based ehealth software company Orion Health is to sell off two significant parts of its business to private equity technology investor Hg for NZ$225 million (US$150.7 million). The sale could revitalise a company that has struggled recently.
Aon’s inaugural Asia Healthcare Trends Report 2017/18 shows that although Hong Kong has a lower medical inflation rate than the average in APAC, it is the highest in Greater China.
Out of date and unsecure fax machines are still being used to share patient information between healthcare providers in Australia. Not only do fax machines cause frustration for healthcare providers trying to communicate with each other, they can also cause patient harm.
Health and well-being programmes are fragmented and do not meet the needs of stressed Asia workforces, finds Willis Towers Watson. By and large, employers in Asia still miss the mark when it comes to their health and well-being benefits, with many employees feeling that their needs are not met, according to research from the global advisory, broking and solutions company.
According to a survey of biopharma companies by L.E.K. Consulting, the majority of firms from Western Europe or the US are interested in China, specifically those at Phase 2 or later development.
Sara Jost, global healthcare industry lead at BlackBerry, explains that putting the systems and procedures in place to deliver a healthy and secure digital healthcare system will protect patient health information and support medical innovation.
my images

Podcasts

HealthInvestor Asia twitter feed